3Pharma
ActiveSummary
3Pharma has been active since 2016 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (-€18,557) and a net result of -€3. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 19% of 22,027 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 1.1% (low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
11-06
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
25-08
NBB filing
Annual accounts filed
financial year 2024 · micro format · 25 days late
2024
06-09
NBB filing
Annual accounts filed
financial year 2023 · micro format · 37 days late
2023
01-09
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format · 32 days late
2022
31-12
Financial
Back to profitnet €25,450
Net result €25,450 after one loss-making year.
04-11
NBB filing
Annual accounts filed
financial year 2021 · micro format · 96 days late
2021
31-12
Financial
Weakest financial yearnet -€44,876
Net result drops to -€44,876, the lowest in the series; recovery starts the following year.
29-11
NBB filing
Annual accounts filed
financial year 2020 · micro format · 121 days late
2020
01-12
NBB filing
Annual accounts filed
financial year 2019 · micro format · 123 days late
2019
31-12
Financial
Back to profitnet €33,010
Net result €33,010 after one loss-making year.
30-08
NBB filing
Annual accounts filed
financial year 2018 · micro format · 30 days late
2018
29-08
NBB filing
Annual accounts filed
financial year 2017 · micro format · 29 days late
2017
29-08
NBB filing
Annual accounts filed
financial year 2016 · micro format · 29 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 4 deeds read
About the unread acts
We know of 4 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.